Recent Finacing
Recent Raise
Biosceptre is a Cambridge-based oncology biotech developing nfP2X7-targeted antibody therapeutics and vaccines, advancing BIL‑221s (a fully human anti-nfP2X7 mAb) into multicentre Phase I dose-escalation trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor